← All trials
NCT02353182
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2015
- Primary completion
- Sep 1, 2016
- Completion date
- Sep 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Murdoch UniversityLead sponsor
- Murdoch UniversityOverall official - principal investigator
- Oregon Health and Science UniversityCollaborator
- KK Women's and Children's HospitalCollaborator
- University of New South WalesCollaborator
- University of PennsylvaniaCollaborator
- Baylor UniversityCollaborator
- Utrecht UniversityCollaborator
- University of GenevaCollaborator
- The University of Texas, DallasCollaborator
- University of RochesterCollaborator
- Starship Children's HealthCollaborator
- University of GenoaCollaborator
- Harvard UniversityCollaborator
- University of MelbourneCollaborator
- University of Western AustraliaCollaborator
- University of CincinnatiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.